文献速递炎症性肠病

儿童炎症性肠病患者SARS-CoV-2疫苗接种的体液免疫应答与安全性

Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2022-09-16

该研究纳入280例5-17岁炎症性肠病(IBD)患儿,评估BNT162b2疫苗接种安全性和体液免疫应答。仅1例因不良事件需急诊或住院;99例检测抗体者中98例可检出,平均抗体水平43.0 μg/mL(SD 67),中位22 μg/mL(IQR 12-38)。调整分析中,年龄较大(P=0.028)和抗肿瘤坏死因子单药治疗相比免疫调节剂单药(P=0.005)与抗体水平降低相关。

要点

  • 儿童IBD患者接种BNT162b2后体液免疫应答稳健,抗体可检出率高。
  • 严重疫苗相关不良事件罕见,仅1例需急诊或住院。
  • 抗肿瘤坏死因子单药治疗和年龄较大与抗体水平降低相关。

核心结论

  • 儿童IBD患者对COVID-19疫苗的体液免疫应答稳健,尽管该儿科队列中高比例患者正在接受免疫抑制治疗。
  • 严重疫苗相关不良事件罕见。
  • 总体而言,这些发现为儿童IBD患者对SARS-CoV-2疫苗接种应答良好且安全提供了高度保证。

研究设计与样本

  • 研究招募了5-17岁、已接种≥2剂BNT162b2疫苗的IBD患儿,通过直接联系患者和选定的中心进行。
  • 收集了患者人口学特征、IBD特征、用药情况和疫苗不良事件。
  • 部分参与者在完成2剂免疫后进行了抗受体结合域IgG抗体定量检测。
  • 研究人群包括280名参与者。

主要发现

  • 280名参与者中,仅1名因不良事件需要急诊就诊或住院。
  • 99名进行抗受体结合域IgG抗体检测的参与者中,98名可检出抗体,平均抗体水平为43.0 μg/mL(SD 67),中位数为22 μg/mL(四分位距12-38)。
  • 在调整分析中,年龄较大(P = 0.028)和抗肿瘤坏死因子单药治疗相比免疫调节剂单药(P = 0.005)与抗体水平降低相关。
  • 接受抗肿瘤坏死因子联合治疗与单药治疗相比,抗体应答在数值上较低但无统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Children with inflammatory bowel disease (IBD) may respond differently to COVID-19 immunization as compared with healthy children or adults with IBD. Those younger than 12 years receive a lower vaccine dose than adults. We sought to describe the safety and humoral immune response to COVID-19 vaccine in children with IBD. METHODS: We recruited children with IBD, ages 5-17 years, who received ≥ 2 doses of the BNT162b2 vaccine by a direct-to-patient outreach and at select sites. Patient demographics, IBD characteristics, medication use, and vaccine adverse events were collected. A subset of participants had quantitative measurement of anti-receptor binding domain IgG antibodies after 2-part immunization. RESULTS: Our study population included 280 participants. Only 1 participant required an ED visit or hospitalization because of an adverse event. Of 99 participants who underwent anti-receptor binding domain IgG antibody measurement, 98 had a detectable antibody, with a mean antibody level of 43.0 μg/mL (SD 67) and a median of 22 μg/mL (interquartile range 12-38). In adjusted analyses, older age ( P = 0.028) and antitumor necrosis factor monotherapy compared with immunomodulators alone ( P = 0.005) were associated with a decreased antibody level. Antibody response in patients treated with antitumor necrosis factor combination vs monotherapy was numerically lower but not significant. DISCUSSION: Humoral immune response to COVID-19 immunization in children with IBD was robust, despite a high proportion of this pediatric cohort being treated with immunosuppressive agents. Severe vaccine-related AEs were rare. Overall, these findings provide a high level of reassurance that pediatric patients with IBD respond well and safely to SARS-CoV-2 vaccination.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kastl AJ, Weaver KN, Zhang X, et al. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 36114773. doi:10.14309/ajg.0000000000002016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。